ECSP045108A - SOLID FORMULATION TO USE AS A MEDICINAL BASED ON A PIPERAZINUREA DERIVATIVE - Google Patents

SOLID FORMULATION TO USE AS A MEDICINAL BASED ON A PIPERAZINUREA DERIVATIVE

Info

Publication number
ECSP045108A
ECSP045108A EC2004005108A ECSP045108A ECSP045108A EC SP045108 A ECSP045108 A EC SP045108A EC 2004005108 A EC2004005108 A EC 2004005108A EC SP045108 A ECSP045108 A EC SP045108A EC SP045108 A ECSP045108 A EC SP045108A
Authority
EC
Ecuador
Prior art keywords
piperazinurea
derivative
solid formulation
medicinal
medicinal based
Prior art date
Application number
EC2004005108A
Other languages
Spanish (es)
Inventor
Heiko Kranz
Christoph Voelkel
Ralph Lipp
Johannes Tack
Herbert Wiesinger
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Ag filed Critical Schering Ag
Publication of ECSP045108A publication Critical patent/ECSP045108A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La invención se refiere a una formulación sólida para utilizar como medicamento que contiene (2R)-1-((4-cloro-2-(ureido)fenoxi) metil)carbonil-2- metil-4-(4-fluoro- bencil)-piperazina o una de sus salesThe invention relates to a solid formulation for use as a medicament containing (2R) -1 - ((4-chloro-2- (ureido) phenoxy) methyl) carbonyl-2- methyl-4- (4-fluorobenzyl) -piperazine or one of its salts

EC2004005108A 2001-10-18 2004-05-17 SOLID FORMULATION TO USE AS A MEDICINAL BASED ON A PIPERAZINUREA DERIVATIVE ECSP045108A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10152351A DE10152351B4 (en) 2001-10-18 2001-10-18 Solid drug formulation for a piperazine urea derivative

Publications (1)

Publication Number Publication Date
ECSP045108A true ECSP045108A (en) 2004-06-28

Family

ID=7703496

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2004005108A ECSP045108A (en) 2001-10-18 2004-05-17 SOLID FORMULATION TO USE AS A MEDICINAL BASED ON A PIPERAZINUREA DERIVATIVE

Country Status (23)

Country Link
EP (1) EP1435917A1 (en)
JP (1) JP2005506365A (en)
KR (1) KR20040047920A (en)
CN (1) CN1571660A (en)
AR (1) AR037111A1 (en)
AU (1) AU2002333896B2 (en)
BR (1) BR0213340A (en)
CA (1) CA2463951A1 (en)
CO (1) CO5580740A2 (en)
DE (1) DE10152351B4 (en)
EC (1) ECSP045108A (en)
HR (1) HRP20040435A2 (en)
IL (1) IL161166A0 (en)
MX (1) MXPA04003522A (en)
NO (1) NO20042022L (en)
NZ (1) NZ532287A (en)
PE (1) PE20030472A1 (en)
PL (1) PL367987A1 (en)
RS (1) RS32204A (en)
RU (1) RU2311172C2 (en)
UY (1) UY27500A1 (en)
WO (1) WO2003035037A1 (en)
ZA (1) ZA200403781B (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1723196A (en) 2001-06-27 2006-01-18 史密丝克莱恩比彻姆公司 Fluoropyrrolidines as dipeptidyl peptidase inhibitors
EP1749519A1 (en) 2005-08-05 2007-02-07 Schering Aktiengesellschaft Dosage form with pH-independent sustained release for active substances with pH-dependent solubility
HUE029173T2 (en) * 2006-04-26 2017-02-28 Alphapharm Pty Ltd Controlled release formulations comprising uncoated discrete unit(s) and an extended release matrix
DE102008047910A1 (en) 2008-09-19 2010-03-25 Molkerei Meggle Wasserburg Gmbh & Co. Kg Tabletting excipient based on lactose and cellulose
KR101654582B1 (en) 2016-05-12 2016-09-06 그린로드(주) Conical Shaped Buoyant Polymer Filter and Apparatus for Manufacturing the same and Method for Manufacturing the same and Water Treatment Filter including the same
RU2729223C1 (en) * 2020-05-13 2020-08-05 Мераб Георгиевич Чикобава Dosage form for amplification of nucleic acids

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1246383B (en) * 1990-04-17 1994-11-18 Eurand Int METHOD FOR MASKING THE TASTE OF DRUGS
FR2668945B1 (en) * 1990-11-12 1993-02-19 Theramex NEW PROCESS FOR THE CRYSTALLIZATION OF ORGANIC SUBSTANCES AND THE COMPOUNDS THUS OBTAINED.
US5705190A (en) * 1995-12-19 1998-01-06 Abbott Laboratories Controlled release formulation for poorly soluble basic drugs
US6004996A (en) * 1997-02-05 1999-12-21 Hoffman-La Roche Inc. Tetrahydrolipstatin containing compositions
US6207665B1 (en) * 1997-06-12 2001-03-27 Schering Aktiengesellschaft Piperazine derivatives and their use as anti-inflammatory agents
TR200002248T2 (en) * 1998-02-05 2000-12-21 Pfizer Products Inc. New dihydroxyhexanoic acid derivatives
ATE400251T1 (en) * 1999-02-09 2008-07-15 Pfizer Prod Inc COMPOSITIONS OF BASIC DRUGS WITH IMPROVED BIOAVAILABILITY

Also Published As

Publication number Publication date
MXPA04003522A (en) 2004-07-23
IL161166A0 (en) 2004-08-31
DE10152351A1 (en) 2003-05-08
BR0213340A (en) 2004-10-05
CA2463951A1 (en) 2003-05-01
WO2003035037A1 (en) 2003-05-01
NO20042022L (en) 2004-05-14
CN1571660A (en) 2005-01-26
CO5580740A2 (en) 2005-11-30
UY27500A1 (en) 2003-06-30
RS32204A (en) 2006-10-27
AU2002333896B2 (en) 2007-07-26
NZ532287A (en) 2007-04-27
KR20040047920A (en) 2004-06-05
RU2311172C2 (en) 2007-11-27
AR037111A1 (en) 2004-10-20
RU2004115328A (en) 2005-06-10
PE20030472A1 (en) 2003-06-16
JP2005506365A (en) 2005-03-03
HRP20040435A2 (en) 2005-06-30
ZA200403781B (en) 2004-11-29
DE10152351B4 (en) 2005-09-22
EP1435917A1 (en) 2004-07-14
PL367987A1 (en) 2005-03-21
AU2002333896A2 (en) 2003-05-06

Similar Documents

Publication Publication Date Title
UY28342A1 (en) NEW COMPOUNDS
CL2009001279A1 (en) Nociceptin derived compounds; pharmaceutical composition comprising said compound; and use of the compound for the treatment of pain (sol. divisional 2103-03).
UY28348A1 (en) NEW COMPOUNDS
ECSP034774A (en) PIRAZOLOPIRIMMIDINAS AS THERAPEUTIC AGENTS
ECSP034773A (en) PIRAZOLOPIRIMMIDINAS AS THERAPEUTIC AGENTS
CR7362A (en) PHARMACEUTICAL FORMULATIONS OF PLATINUM DERIVATIVE
HN2003000407A (en) NEW DERIVATIVES OF AROMATIC FLUOROGLYCOSISES, MEDICINES CONTAINING THESE COMPOUNDS AND THEIR USES.
SV2004001690A (en) NEW DERIVATIVES OF HETEROCICLIC FLUOROGLYCOSIDS, MEDICINES CONTAINING THESE COMPOUNDS, AND THE USE OF THE SAME
UY27516A1 (en) BENCIMIDAZOLS
ECSP066365A (en) ANILINO PURINAS REPLACED IN POSITION 6 USEFUL AS RTK INHIBITORS
MXPA05012573A (en) Pyrazolo-quinazoline derivatives,process for their preparation and their use as kinase inhibitors.
UY28572A1 (en) NEW COMPOUNDS
PA8548701A1 (en) AZAINDOLS
SV2005001979A (en) "PIRIDO [2,3-D] PIRIMIDINA-2,4-DIAMINAS AS PDE 2 INHIBITORS" REF. PC25123A
PA8570901A1 (en) DERIVATIVES OF ACIL-4-CARBOXIFENILUREA, PROCEDURES FOR PREPARATION AND USE
PA8582801A1 (en) NEW SPIROTRICYCLIC DERIVATIVES AND THEIR USE AS INHIBITORS OF PHOSPHODIESTERASE
CY1110130T1 (en) MORPHOLINE PRODUCTS FOR USE AS DOPAMINE AGONISTS IN THERAPEUTIC DISEASE Therapeutic Treatment I.A.
AR045572A1 (en) A COMBINATION THAT INCLUDES N- (3-METOXI-5-METHYLPIRAZIN-2-IL) -2- (4- [1,3,4-OXADIAZOL-2-IL] PHENYL-3-SULFONAMIDE AND AN ANALOG LHRH AND / OR A bisphosphonate
ECSP045493A (en) NEW PHARMACEUTICAL COMPOSITIONS CONTAINING FLIBANSERINE POLYMORPH A
PA8586801A1 (en) HIV-INTEGRESS INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE
AR041340A1 (en) DERIVATIVES OF THIAZOLPIRIMIDINONE, PREPARATION PROCESS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
AR041339A1 (en) DERIVATIVES OF THIAZOLPIRIMIDINONE, PREPARATION PROCESS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
HN2001000235A (en) DERIVATIVES BRIDGES OF PIPERAZINA
UY27500A1 (en) SOLID FORMULATION TO USE AS A MEDICINAL BASED ON A PIPERAZINUREA DERIVATIVE
CR8178A (en) EMULSION SYSTEMS CONTAINING DERIVATIVES OF AZETIDINE